Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
NCT00332319 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1
Last updated 2015-04-17
Summary
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry. Part B will assess the effect of repeat doses of GW679769 on the bladder nerve function. Part B will also assess the effects of the drug on overactive bladder symptoms using a three-day patient diary.
Conditions
- Incontinence, Urinary and Urinary Bladder, Overactive
- Overactive Bladder
Interventions
- DRUG
-
GW679769
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-01-31
- Primary Completion
- 2007-02-28
- Completion
- 2007-02-28
Countries
- United States
Study Locations
More Related Trials
-
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
NCT00224029 ·Status: COMPLETED ·Phase: PHASE4
-
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
NCT04227184 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563 ·Status: COMPLETED ·Phase: PHASE2
-
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
NCT00231790 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms
NCT04999657 ·Status: COMPLETED ·Phase: NA
-
Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
NCT00780832 ·Status: TERMINATED ·Phase: NA
-
Urge Incontinence Bladder Overactivity Study
NCT00475696 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms
NCT04758247 ·Status: COMPLETED ·Phase: NA
-
Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial
NCT05157295 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
NCT00629642 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
NCT00196404 ·Status: COMPLETED ·Phase: PHASE2
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
NCT03817931 ·Status: COMPLETED ·Phase: PHASE4
-
TPTNS: Home vs Hospital Treatment for Overactive Bladder
NCT03727711 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
NCT04545580 ·Status: COMPLETED ·Phase: PHASE2
-
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
NCT00507169 ·Status: COMPLETED ·Phase: PHASE2
-
Sexual Function Trial of Overactive Bladder: Medication Versus PTNS
NCT03500146 ·Status: COMPLETED
-
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
NCT00481728 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
NCT01029015 ·Status: COMPLETED
-
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
NCT05162833 ·Status: COMPLETED ·Phase: NA
-
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104 ·Status: COMPLETED ·Phase: PHASE3
-
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
NCT05719285 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
NCT00335660 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
NCT03168828 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
NCT01598103 ·Status: TERMINATED ·Phase: PHASE2